The potential role of fatty liver in paediatric metabolic syndrome: A distinct phenotype with high metabolic risk?

Pediatric Obesity

Volumn 7, Issue 6, 2012, Pages e75-e80

  Nobili, V ^a,i   Bedogni, G ^b,c,i   Berni Canani, R ^d,i   Brambilla, P ^e,i   Cianfarani, S ^a,f,i   Pietrobelli, A ^g,h,i   Agostoni, C ^b,i  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b Liver Research Center   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e Azienda Sanitaria Locale (ASL) Milano 2   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g UNIVERSITY OF VERONA   (Italy)

^h PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

ⁱ Italian Hobbit Network on Pediatric Nutrition   (Italy)

Author keywords

Insulin resistance metabolic syndrome; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

GLUCOSE; INSULIN; TRIACYLGLYCEROL;

ADIPOSE TISSUE; CHILDHOOD OBESITY; DISEASE ASSOCIATION; FATTY LIVER; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84872796006     PISSN: 20476302     EISSN: 20476310     Source Type: Journal    
DOI: 10.1111/j.2047-6310.2012.00079.x     Document Type: Review

References (57)

1. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480.
2. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
3. Zimmet P, Alberti KG, Kaufman F, et al. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes 2007; 8: 299-306.
4. Simmons RK, Alberti KG, Gale EA, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2010; 53: 600-605.
5. Reaven GM. The metabolic syndrome: time to get off the merry-go-round? J Intern Med 2011; 269: 127-136.
6. Prabhakaran D, Reddy KS. The metabolic syndrome: looking beyond the debates. Clin Pharmacol Ther 2011; 90: 19-21.
7. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285.
8. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-384.
9. Moscatiello S, Di Luzio R, Sasdelli AS, Marchesini G. Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome. Expert Opin Pharmacother 2011; 12: 2657-2672.
10. Perseghin G. Viewpoints on the way to a consensus session: where does insulin resistance start? The liver. Diabetes Care 2009; 32(Suppl. 2): S164-S167.
11. Deivanayagam S, Mohammed BS, Vitola BE, et al. Nonalcoholic fatty liver disease is associated with hepatic and skeletal muscle insulin resistance in overweight adolescents. Am J Clin Nutr 2008; 88: 257-262.
12. Juurinen L, Tiikkainen M, Häkkinen AM, Hakkarainen A, Yki-Järvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292: E829-E835.
13. Sevastianova K, Sutinen J, Kannisto K, Hamsten A, Ristola M, Yki-Järvinen H. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab 2008; 295: E85-E91.
14. Perseghin G. The role of non-alcoholic fatty liver disease in cardiovascular disease. Dig Dis 2010; 28: 210-213.
15. Nobili V, Bedogni G, Alisi A, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 2011; 96: 350-353.
16. Manco M, Bedogni G, Marcellini M, et al. Waist circumference correlates with liver fibrosis in children with nonalcoholic steatohepatitis. Gut 2008; 57: 1283-1287.
17. Brambilla P, Bedogni G, Moreno LA, et al. Cross validation of anthropometry against magnetic resonance imaging for the assessment of visceral and subcutaneous adipose tissue in children. Int J Obes (Lond) 2006; 30: 23-30.
18. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887.
19. Kumashiro N, Erion DM, Zhang D, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 2011; 108: 16381-16385.
20. Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 2004; 117: 421-426.
21. Valenti L, Rametta R, Dongiovanni P, et al. Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes 2008; 57: 1355-1362.
22. Michael MD, Kulkarni RN, Postic C, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000; 6: 87-97.
23. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44: 27-33.
24. Bradbury MW. Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. Am J Physiol Gastrointest Liver Physiol 2006; 290: G194-G198.
25. Nobili V, Bedogni G, Alisi A, et al. A protective effect of breastfeeding on the progression of non-alcoholic fatty liver disease. Arch Dis Child 2009; 94: 801-805.
26. Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids - a promising novel therapy for nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2010; 31: 679-692.
27. Strable MS, Ntambi JM. Genetic control of de novo lipogenesis: role in diet-induced obesity. Crit Rev Biochem Mol Biol 2010; 45: 199-214.
28. Visser ME, Lammers NM, Nederveen AJ, et al. Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia. Diabetologia 2011; 54: 2113-2121.
29. Schonfeld G, Yue P, Lin X, Chen Z. Fatty liver and insulin resistance: not always linked. Trans Am Clin Climatol Assoc 2008; 119: 217-223.
30. Amaro A, Fabbrini E, Kars M, et al. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology 2010; 139: 149-153.
31. Savage DB, Semple RK. Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. Curr Opin Lipidol 2010; 21: 329-336.
32. Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2007; 13: 3540-3553.
33. Mirza MS. Obesity, visceral fat, and NAFLD: querying the role of adipokines in the progression of nonalcoholic fatty liver disease. ISRN Gastroenterol 2011; 2011: 1-11.
34. Valle M, Martos R, Gascón F, Cañete R, Zafra MA, Morales R. Low-grade systemic inflammation, hypoadiponectinemia and a high concentration of leptin are present in very young obese children, and correlate with metabolic syndrome. Diabetes Metab 2005; 31: 55-62.
35. Herder C, Schneitler S, Rathmann W, et al. Low-grade inflammation, obesity, and insulin resistance in adolescents. J Clin Endocrinol Metab 2007; 92: 4569-4574.
36. Nobili V, Manco M, Ciampalini P, et al. Leptin, free leptin index, insulin resistance and liver fibrosis in children with nonalcoholic fatty liver disease. Eur J Endocrinol 2006; 155: 735-743.
37. Madeira IR, Bordallo MA, Carvalho CN, et al. The role of metabolic syndrome components and adipokines in insulin resistance in prepubertal children. J Pediatr Endocrinol Metab 2011; 24: 289-295.
38. Tilg H. Adipocytokines in nonalcoholic fatty liver disease: key players regulating steatosis, inflammation and fibrosis. Curr Pharm Des 2010; 16: 1893-1895.
39. Fitzpatrick E, Mitry RR, Quaglia A, Hussain MJ, DeBruyne R, Dhawan A. Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr 2010; 51: 500-506.
40. Pyrzak B, Ruminska M, Popko K, Demkow U. Adiponectin as a biomarker of the metabolic syndrome in children and adolescents. Eur J Med Res 2010; 15(Suppl. 2): 147-151.
41. Louthan MV, Barve S, McClain CJ, Joshi-Barve S. Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. J Pediatr 2005; 147: 835-838.
42. Murdolo G, Nowotny B, Celi F, et al. Inflammatory adipokines, high molecular weight adiponectin, and insulin resistance: a population-based survey in prepubertal schoolchildren. PLoS ONE 2011; 6: e17264.
43. Lebensztejn DM, Wojtkowska M, Skiba E, Werpachowska I, Tobolczyk J, Kaczmarski M. Serum concentration of adiponectin, leptin and resistin in obese children with nonalcoholic fatty liver disease. Adv Med Sci 2009; 54: 177-182.
44. Alikaşifoǧlu A, Gönç N, Özön ZA, Sen Y, Kandemir N. The relationship between serum adiponectin, tumor necrosis factor-alpha, leptin levels and insulin sensitivity in childhood and adolescent obesity: adiponectin is a marker of metabolic syndrome. J Clin Res Pediatr Endocrinol 2009; 1: 233-239.
45. Galcheva SV, Iotova VM, Yotov YT, Bernasconi S, Street ME. Circulating proinflammatory peptides related to abdominal adiposity and cardiometabolic risk factors in healthy pre-pubertal children. Eur J Endocrinol 2011; 164: 553-558.
46. Alisi A, Manco M, Devito R, Piemonte F, Nobili V. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2010; 50: 645-649.
47. Nobili V, Carpino G, Alisi A, et al. Hepatic progenitor cell activation, fibrosis and adipokine production in pediatric nonalcoholic fatty liver disease. Hepatology 2012; doi: 10.1002/hep.25742 (accepted article).
48. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012; 142: 711-725.e6.
49. Alisi A, Cianfarani S, Manco M, Agostoni C, Nobili V. Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. Ann Med 2012; 44: 29-40.
50. Lattuada G, Ragogna F, Perseghin G. Why does NAFLD predict type 2 diabetes? Curr Diab Rep 2011; 11: 167-172.
51. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A 2009; 106: 15430-15435.
52. Fabbrini E, Tamboli RA, Magkos F, et al. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology 2010; 139: 448-455.
53. Alisi A, Locatelli M, Nobili V. Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care 2010; 13: 397-402.
54. Patton HM, Yates K, Unalp-Arida A, et al. Association between metabolic syndrome and liver histology among children with nonalcoholic fatty liver disease. Am J Gastroenterol 2010; 105: 2093-2102.
55. Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010; 69: 211-220.
56. Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem 2012; 23: 203-208.
57. Lonardo A, Bellentani S, Ratziu V, Loria P. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies? Expert Rev Gastroenterol Hepatol 2011; 5: 279-289.